Nephrology

Asahikawa, Japan

Nephrology

Asahikawa, Japan

Time filter

Source Type

News Article | May 9, 2017
Site: www.prnewswire.com

Another research by Global Market Insights indicates that strong R&D spending trends for synthetic biology to enable drug and vaccine development, including Europe NEST program will stimulate growth. Organizations including DBT (Department of Biotechnology) and NTBT (National Biotechnology Board) provides funding for promoting biotechnology market share. The U.S. biotechnology market size held a dominant position in terms of industry revenue share, with Europe following. This trend is likely to continue throughout the forecast period. The U.S. will further see increased adoption of products based on these platforms, as growth for personalized medicine becomes a preference. Quest PharmaTech Inc. (TSX-V: QPT) is a pharmaceutical company developing and commercializing products to improve the quality of life. Just this morning the company announced that its subsidiary, OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer has completed the enrollment of the first patient in a Phase 1/2 clinical study to evaluate the use of oregovomab in combination with Nivolumab, an anti-PD1 human monoclonal antibody which works as a checkpoint inhibitor in ovarian cancer patients in the recurrent setting. This clinical trial is being conducted at the National Cancer Centre in Singapore ("NCCS"), with Dr. Tira Tan as Principal Investigator, Adjunct Associate Professor John Chia from Oncocare Cancer Centre as the Study Chair, and Dr. Jack Chan as the co-chair. "We are extremely excited about launching this study," noted Dr. John Chia. "Ovarian cancer is a lethal disease, and this trial may offer new hope for our patients. Early clinical data suggests that oregovomab may improve the immune system's processing of cancer antigens, and enhance the immune ability to recognize these cancer targets. We believe that the combination of oregovomab and Nivolumab, which amplifies such immune activity, will have a synergistic effect to elicit a higher quality tumor immune response, and hence improve control of the cancer." This will be the first clinical trial testing the combination of oregovomab with a checkpoint inhibitor as potential treatment of ovarian cancer in the recurrent setting. "We continue to explore the potential of oregovomab in various stages of the progression of ovarian cancer," said Dr. Madiyalakan, CEO of Quest and OncoQuest. In frontline ovarian cancer, OncoQuest has recently announced positive interim results from its randomized controlled multi-center Phase 2 clinical trial with oregovomab as an indirect immunizer, in scheduled combination with carboplatin and paclitaxel. "In the recurrent setting, we are exploring the use of oregovomab with immune adjuvants in two clinical trials. The trial NCCS is conducting is in combination with a checkpoint inhibitor. We are also in the process of initiating a trial in U.S. in combination with a TLR3 agonist, Hiltonol®," continued Dr. Madiyalakan. Theratechnologies Inc. (OTC: THERF) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Recently, the company announced that its partner, TaiMed Biologics, Inc., has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ibalizumab for the treatment of multidrug resistant Human Immunodeficiency Virus-1 (MDR HIV-1). If approved, ibalizumab will be the first antiretroviral treatment (ART) with a new mechanism of action to be introduced in nearly 10 years and the only treatment that does not require daily dosing. CRH Medical Corporation (NYSE: CRHM) is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. On March 15, 2017, the company announced that it has completed an accretive transaction whereby CRH has acquired a 60% interest in a gastroenterology ("GI") anesthesia practice in Kissimmee Florida ("Kissimmee"). CRH also announces that it has entered into an exclusive agreement to develop and manage a monitored anesthesia care ("MAC", or "Deep Sedation") program with Puget Sound Gastroenterology ("PSG"), located in Washington State. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) a clinical stage biopharmaceutical company focused on the global immunology market, today announced additional 48-week results from its global Phase IIb AURA-LV (AURA) study in lupus nephritis (LN) during the National Kidney Foundation 2017 Spring Clinical Meetings in Orlando, FL. In addition to the trial meeting its complete and partial remission ("CR"/"PR") endpoints at 48 weeks, all pre-specified secondary endpoints that have been analyzed to date were also met at 48 weeks. These pre-specified endpoints include: time to CR and PR (speed of remission); reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in urine protein creatinine ratio (UPCR) over the 48-week treatment period. The data were presented during the late-breaking session by lead author Dr. Samir Parikh, a clinical investigator for the study and Assistant Professor of Clinical Nephrology at the Ohio State University. Concordia International Corp. (NASDAQ: CXRX) together with its subsidiaries is an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs. On January 3rd, the company announced it has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. through which the companies expect to expand sales of Donnatal®, Concordia's product used in the treatment of irritable bowel syndrome. Concordia's North America segment seeks to acquire and manage drugs that are in the maturity or legacy stage of the pharmaceutical product lifecycle and continue on a predictable revenue generation path. These products have a well-established record of safety and efficacy and a history of stable demand. Please Sign Up Now at http://www.FinancialBuzz.com to receive alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News" Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/ FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications. Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated four thousand dollars for financial news dissemination and PR services by a third party non affiliate for Quest PharmaTech Inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com


The objectives of the meeting are to identify both the current state of and the greatest opportunities in the three identified aspects of primary palliative nursing. The post meeting objectives are to develop an implementation plan, and to identify strategies to address the greatest opportunities to help nursing transform the care and culture of serious illness. National initiatives over the last few years have helped set the stage for this summit by identifying significant opportunities to enhance care delivery models and systems.  Those gathering from the nursing community at the summit will help create a collaborative agenda to focus on how nurses lead and transform care for individuals and their families who are facing serious illness. Attending organizations include the Academy of Medical-Surgical Nurses (AMSN), Academy of Neonatal Nursing (ANN), American Academy of Ambulatory Care Nursing (AAACN), American Association of Critical-Care Nurses (AACN), American Association of Neuroscience Nurses (AANN), American Association of Nurse Practitioners (AANP), American Holistic Nurses Association (AHNA), American Nephrology Nurses Association (ANNA), American Nurses Association (ANA), American Psychiatric Nurses Association (APNA), American Society for Pain Management Nursing (ASPMN), Association for Radiologic and Imaging Nursing (ARIN), Association of Pediatric Hematology/Oncology Nurses (APHON), Association of Rehabilitation Nurses (ARN), Emergency Nurses Association (ENA), Gerontological Advanced Practice Nurses Association (GAPNA), Home Healthcare Nurses Association (HHNA), Hospice and Palliative Nurses Association (HPNA), Infusion Nurses Society (INS), International Transplant Nurses Society (ITNS), National Association of Clinical Nurse Specialists (NACNS), National Association of Directors of Nursing Administration (NADONA), National Association of Pediatric Nurse Practitioners (NAPNAP), Nurses Organization of Veterans Affairs (NOVA), Oncology Nursing Society (ONS), and the Wound Ostomy and Continence Nurses Society (WOCN).  These organizations collectively represent over 610,000 members. The summit is also supported through the Institute for Healthcare Improvement and hosted by the George Washington University School of Nursing. The Palliative Nursing Summit was made possible through grants from the Milbank Foundation and the Hospice and Palliative Nurses Foundation. Those interested in the Palliative Nursing Summit can follow along through social media on Twitter and Facebook by using the #palliative, #nursingsummit, and #nursing hashtags.  Additional information is online at advancingexpertcare.org/palliative-nursing-summit. About HPNA The Hospice and Palliative Nurses Association was established in 1986 and is the national professional organization that represents the specialty of palliative nursing, which includes hospice and palliative nurses. HPNA has over 11,500 members and 50 chapters nationally.  HPNA works together with the Hospice and Palliative Credentialing Center and the Hospice and Palliative Nurses Foundation to promote our mission, to advance expert care in serious illness, and our vision, to transform the care and culture of serious illness. Visit hpna.advancingexpertcare.org  to learn more. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/25-specialty-nursing-organizations-join-with-the-hospice-and-palliative-nurses-association-for-a-palliative-nursing-summit-may-12-in-washington-dc-300453369.html


The International Association of HealthCare Professionals is pleased to welcome Dr. Nicolaos V. Athienites, MD, to their prestigious organization with his upcoming publication in The Leading Physicians of the World. He is a highly trained and qualified nephrologist with a vast expertise in all facets of his work, especially acute kidney failure, amyloidosis and acidosis. Dr. Athienites has been practicing for over three decades and is currently maintaining a position at Renal Medical Care in Brockton, Massachusetts. He is also affiliated with South Shore Hospital and Brigham and Women’s Hospital. Dr. Nicolaos V. Athienites obtained his Medical Degree in 1986, when he graduated from the National and Kapodistrian University of Athens in Greece. After moving to the United States, he completed an internship and residency at Newton-Wellesley Hospital, prior to a fellowship at Tufts Medical Center in Boston. Dr. Athienites is board certified in Nephrology by the American Board of Internal Medicine. To keep up to date with the latest advances and developments in his field, he maintains a professional membership with the American College of Physicians, the American Society of Nephrology and the Massachusetts Medical Society. Alongside his practice, he serves as an Assistant Professor at Tufts University School of Medicine, and attributes his success to his Herculean powers of perseverance. When he is not assisting patients, Dr. Athienites likes to stay fit by using calisthenics and ancient Greek exercises. Learn more about Dr. Athienites by reading his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit: http://www.findatopdoc.com


News Article | May 10, 2017
Site: www.eurekalert.org

(BOSTON) -- The kidney - made up of about a million tiny units that work to filter blood, constantly rids the body of undesired waste products to form urine while holding back blood cells and valuable proteins, and controls the body's fluid content. Key to each of these units is a structure known the 'glomerulus', in which so-called podocyte cells wrap themselves tightly around a tuft of capillaries separated from them only by a thin membrane composed of extracellular matrix, and leaving slits between them to build an actual filtration barrier. Podocytes are also the target of many congenital or acquired kidney diseases, and they are often harmed by drugs. To build an in vitro model of the human glomerulus that could allow probing deeper into its function, as well as its vulnerabilities to disease and drug toxicities, researchers have been attempting to engineer human stem cells -- that in theory can give rise to any mature cell type -- so that they form into functional podocytes. These cell culture efforts, however, so far have failed to produce populations of mature podocytes pure enough as to be useful for modeling glomerular filtration. A team led by Donald Ingber, M.D., Ph.D., at Harvard's Wyss Institute of Biologically Inspired Engineering now reports a solution to this challenge in Nature Biomedical Engineering, which enables the differentiation of human induced pluripotent stem (iPS) cells into mature podocytes with more than 90% efficiency. Linking the differentiation process with organ-on-a-chip technology pioneered by his team, the researchers went on to engineer the first in vitro model of the human glomerulus, demonstrating effective and selective filtration of blood proteins and podocyte toxicity induced by a chemotherapy drug in vitro. Ingber is the Wyss Institute's Founding Director, the Judah Folkman Professor of Vascular Biology at Harvard Medical School (HMS) and the Vascular Biology Program at Boston Children's Hospital, as well as Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS). "The development of a functional human kidney glomerulus chip opens up an entire new experimental path to investigate kidney biology, carry out highly personalized modeling of kidney diseases and drug toxicities, and the stem cell-derived kidney podocytes we developed could even offer a new injectable cell therapy approach for regenerative medicine in patients with life-threatening glomerulopathies in the future," said Ingber. Ingber's team has engineered multiple organs-on-chips that accurately mimic human tissue and organ-level physiology and that are currently being evaluated by the Food and Drug Administration (FDA) as a tool to more effectively study the effects of potential chemical and biological hazards found in foods, cosmetics or dietary supplements than existing culture systems or animal models. In 2013, his team developed an organ-on-a-chip microfluidic culture device that modeled the human kidney's proximal tubule, which is anatomically connected to the glomerulus and salvages ions from urinary fluid. Now, with the team's newly engineered human kidney glomerulus-on-a-chip, researchers also can get in vitro access to the kidney's core filtration mechanisms that are critical for drug clearance and pharmacokinetics, in addition to studying human podocytes at work. To generate almost pure populations of human podocytes in cell culture, Samira Musah, Ph.D., the study's first author and HMS Dean's Postdoctoral Fellow who is working with Ingber at the Wyss Institute, leveraged pieces of the stem cell biologists' arsenal, and merged them with snippets taken from Ingber's past research on how cells in the body respond to adhesive factors and physical forces in their tissue environments. "Our method not only uses soluble factors that guide kidney development in the embryo, but, by growing and differentiating stem cells on extracellular matrix components that are also contained in the membrane separating the glomerular blood and urinary systems, we more closely mimic the natural environment in which podocytes are induced and mature," said Musah. "We even succeeded in inducing much of this differentiation process within a channel of the microfluidic chip, where by applying cyclical motions that mimic the rhythmic deformations living glomeruli experience due to pressure pulses generated by each heart beat, we achieve even greater maturation efficiencies." The complete microfluidic system closely resembles a living, three-dimensional cross-section of the human glomerular wall. It consists of an optically clear, flexible, polymeric material the size of a computer memory chip in which two closely opposed microchannels are separated by a porous, extracellular matrix-coated membrane that corresponds to the kidney's glomerular basement membrane. In one of the membrane-facing channels, the researchers grow glomerular endothelial cells to mimic the blood microvessel compartment of glomeruli. The iPS cells are cultured on the opposite side of the membrane in the other channel that represents the glomerulus' urinary compartment, where they are induced to form a layer of mature podocytes that extend long cellular processes through the pores in the membrane and contact the underlying endothelial cells. In addition, the device's channels are rhythmically stretched and relaxed at a rate of one heart beat per second by applying cyclic suction to hollow chambers placed on either side of the cell-lined microchannels to mimic physiological deformations of the glomerular wall. "This in vitro system allows us to effectively recapitulate the filtration of small substances contained in blood into the urinary compartment while retaining large proteins in the blood compartment just like in our bodies, and we can visualize and monitor the damage inflicted by drugs that cause break-down of the filtration barrier in the kidney," said Musah. The study was also co-authored by Wyss Institute Core Faculty member George Church, Ph.D., who also is Professor of Genetics at HMS and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), and who served as a co-mentor of Musah with Ingber. Other authors include Akiko Mammoto, M.D., Ph.D. and Tadanori Mammoto, M.D., Ph.D., who at the time of the study were Instructors in the Vascular Biology Program and Department of Surgery at Boston Children's Hospital, as well as present or past Wyss Institute researchers, including Thomas Ferrante, Sauveur Jeanty, Kristen Roberts, Seyoon Chung, Ph.D., Richard Novak, Ph.D., Miles Ingram, Tohid Fatanat-Didar, Ph.D., Sandeep Koshy, Ph.D., and James Weaver, Ph.D. Funding for the study was provided by the Defense Advanced Research Projects Agency (DARPA). Musah was supported by a HMS Dean's Postdoctoral Fellowship, Postdoctoral Enrichment Program Award from the Burroughs Wellcome Fund, UNCF-Merck Postdoctoral Fellowship, and an NIH/NIDDK Nephrology Training Grant. The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard's Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston Children's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité - Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.


News Article | May 15, 2017
Site: marketersmedia.com

— Global In-Vitro Diagnostics Market Information by test types (blood, urine, tissue, others) by technology (includes immunochemistry, molecular diagnostics, others) by application (Cancer, Cardiology, Nephrology, Drug Testing, HIV/AIDS) by end users Laboratories, Hospitals, Academic Institutes) - Forecast to 2027 In vitro diagnostic products are those reagents, instruments, and frameworks planned for use in conclusion of sickness or different conditions, including a determination of the condition of health, with a specific end goal to cure, alleviate, treat, or prevent. Such items are planned for use in the accumulation, preparation, and examination of specimens taken from the human body. Study Objectives of In-Vitro Diagnostics Market: • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global In-Vitro Diagnostics Market • To provide insights about factors affecting the market growth • To Analyze the Global In-Vitro Diagnostics Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and RoW • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by test type, by application, by technology by end users and sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global In-Vitro Diagnostics Market Global In-Vitro Diagnostics Market has been segmented on the basis of applications which consist of Infectious Diseases, Cancer, Cardiology, Nephrology, Drug Testing, HIV/AIDS and others On the basis of test types which include blood, urine, tissue and others. On the basis of technology which includes immunochemistry, molecular diagnostics, self-monitoring blood glucose monitoring, point of care testing, hematology, clinical microbiology. On the basis of end users which includes Laboratories, Hospitals, Academic Institutes and others • Abbott Laboratories, Inc (US) • Roche Diagnostics(Switzerland) • Biomérieux (France) • Ortho Clinical Diagnostics (US) • Johnson & Johnson (US) • Siemens Healthineers (Germany) • Sysmex (japan) • Becton Dickinson (US) • Thermo Fisher Scientific Inc. (US) • Accelerate Diagnostics (US) • Hycor Biomedical (US) • Diagnostic Biosystems (US) • Eurogentec (Belgium) • Orgentec Diagnostics (US) • Immunarray PVT. LTD (US) • Werfen Group (Spain) • Danaher Corporation (US) • Bio-Rad Laboratories INC (US) • Stago Diagnostica (France) • Alere Inc (US) Americas • North America o US o Canada • Latin America Europe • Western Europe o Germany o France o Italy o Spain o U.K o Rest of Western Europe • Eastern Europe Asia– Pacific • Asia o China o India o Japan o South Korea o Rest of Asia • Pacific The Middle East& Africa Request for Table of Content at https://www.marketresearchfuture.com/request-toc/1165 . The report for Global In-Vitro Diagnostics Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions For more information, please visit https://www.marketresearchfuture.com/reports/in-vitro-diagnostics-market


News Article | May 17, 2017
Site: www.eurekalert.org

(NEW YORK -- May 17, 2017) Biomarkers in the teeth of wild orangutans indicate nursing patterns related to food fluctuations in their habitats, which can help guide understanding of breast-feeding evolution in humans, according to a study published today in Science Advances. This work was led by researchers in the Department of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai and evolutionary biologists at Griffith University in Australia. Breast-feeding is a critical aspect of human development, and the duration of exclusive nursing and timing of introducing solid food to the diet are also important determinants of health in human and other primate populations. Many aspects of nursing, however, remain poorly understood. Orangutan nursing habits have also been difficult to study due to challenges in observing this behavior in their natural environment. To work around these challenges, researchers reconstructed diet histories of wild orangutans by using their teeth as biomarkers. The growth patterns of teeth, which resemble tree rings, allows investigators to determine concentrations of the maternal elements in the infants' teeth over time, which yields information about their nursing and dietary patterns. "Early-life dietary transitions reflect fundamental aspects of primate life, history, and evolution," said Christine Austin, PhD, a postdoctoral fellow in the Department of Environmental Medicine and Public Health and second study author. "By first studying nursing patterns of our primate cousins, we can apply these findings to future studies in humans. This method can be used to reconstruct the diet histories of contemporary humans in order to reliably and accurately study the relationship between infant diet and health outcomes in childhood or later life, as well as inform models of population growth." In this study, the researchers examined levels of the element barium in teeth samples from deceased Sumatran and Bornean orangutans housed in zoological museums. Teeth analyses showed that the orangutans consumed maternal milk exclusively for their first year, as determined by a gradual increase in barium levels over the first 12 months. After the first year, the teeth indicated cycles that alternated between more and less milk consumption, which may occur until eight to nine years of age, a later weaning age than any other primate. This cycling is believed to result from the changing and unpredictable availability of fruit, which leads young orangutans to rely on maternal milk for a longer period of time. "The evidence of cyclical multi-year nursing patterns and late weaning ages in orangutans, reported here for the first time, will lead to further studies of how food availability and other environmental factors affect nursing patterns in primates," said Tanya Smith, PhD, Associate Professor at Griffith University and lead study author. "Additional research is needed to determine whether similar breast-feeding patterns help human babies increase resilience to environmental stressors in infancy." For more information on exposure biology research at Mount Sinai, please visit http://labs. . The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care. The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the "Honor Roll" of best hospitals in America, ranked No. 15 nationally in the 2016-2017 "Best Hospitals" issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai's Kravis Children's Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in "Best Children's Hospitals." For more information, visit http://www. , or find Mount Sinai on Facebook, Twitter and YouTube.

Loading Nephrology collaborators
Loading Nephrology collaborators